Welcome to our dedicated page for Agenus SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Agenus Inc. (NASDAQ: AGEN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a publicly traded immuno-oncology developer. As a filer under the Securities Exchange Act of 1934, Agenus uses Forms 8-K, 10-Q, 10-K and proxy materials to report financial results, clinical and corporate milestones, and shareholder actions related to its cancer immunotherapy programs.
Recent Form 8-K filings illustrate how these documents track material events. Agenus has furnished quarterly financial results for periods in 2025, reported on its annual meeting of stockholders and voting outcomes on director elections and equity plans, and described a promissory note agreement with a Zydus Lifesciences subsidiary tied to the planned sale of its Emeryville and Berkeley biologics manufacturing facilities. Other 8-Ks outline progress on the broader asset purchase, stock purchase and license agreements with Zydus, including updates on the Committee on Foreign Investment in the United States (CFIUS) review process.
For investors analyzing Agenus, periodic reports such as Forms 10-Q and 10-K (when available) are central to understanding the company’s financial condition, risk factors and research and development focus in immuno-oncology. These filings typically discuss the BOT+BAL clinical program, broader pipeline of antibody therapeutics, adoptive cell therapies and adjuvants, and the company’s development capabilities and collaborations.
On Stock Titan, each new Agenus filing is captured from EDGAR and paired with AI-powered summaries designed to highlight the most important points—such as key terms of financing arrangements, updates on the Zydus collaboration, or changes in capital structure. Users can also review Forms 4 and related ownership reports to monitor insider transactions in AGEN shares. This centralized view helps readers navigate complex SEC documents and quickly identify information relevant to Agenus’ immuno-oncology strategy, clinical progress and corporate governance.
Agenus Inc. reported an update on its previously announced transactions with Zydus Pharmaceuticals (USA) Inc., involving the sale of its manufacturing operations, a minority equity investment by Zydus, and a license granting Zydus commercial rights in India and Sri Lanka for BOT/BOL-related intellectual property. The companies had already submitted an initial filing to the Committee on Foreign Investment in the United States (CFIUS).
On September 17, 2025, CFIUS requested that Agenus and Zydus voluntarily submit a full notice application for these transactions. As a result of the expected timing of this extended CFIUS review, Agenus now anticipates that the closing of the transactions will occur in the fourth quarter of 2025 rather than earlier.
Garo H. Armen, Chairman and CEO of Agenus Inc. (AGEN), reported a non-derivative acquisition on 09/19/2025. At his request and with Compensation Committee approval, Mr. Armen’s salary for the pay period ending September 19, 2025, was paid in stock: 3,734 shares of Common Stock were issued at a closing price of $4.38. Those shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and were fully vested on issuance. Following the transaction the filing shows Mr. Armen beneficially owning 278,442 shares directly, 31,298 shares held in his IRA accounts, and 28,950 shares indirectly through trustee and partnership arrangements. The form was signed by an attorney-in-fact on 09/23/2025.
Garo H. Armen, Chairman and CEO of Agenus Inc. (AGEN), received 3,778 shares of common stock as payment of salary for the pay period ending September 5, 2025. The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and were fully vested on issuance. The report shows a per-share value of $4.33, the closing price on September 5, 2025. Following this issuance, Dr. Armen beneficially owns 274,708 shares directly and additional indirect holdings reported as 31,298 and 28,950 shares held in IRA accounts and other vehicles described in the footnotes. The Form 4 was signed by an attorney-in-fact on behalf of Dr. Armen on September 8, 2025.
Garo H. Armen received 3,619 shares of Agenus Inc. common stock as salary in lieu of cash for the pay period ending August 22, 2025. The shares were issued at a closing price of $4.52 on August 22, 2025, and are fully vested on issuance under the company's amended 2019 Equity Incentive plan. After the reported issuance, Dr. Armen is shown as beneficial owner of 270,930 shares directly, plus indirect holdings of 31,298 and 28,950 shares tied to his IRA accounts and other entities where he holds trustee or partnership roles.
The Form 4 reflects routine insider compensation reporting rather than an open-market purchase or sale; the filing was signed by an attorney-in-fact on August 25, 2025. Explanatory footnotes state the stock issuance was approved by the Agenus Compensation Committee and represents net salary for the stated payroll period.
Agenus Inc. reported a six-month net loss of $56.4 million and a weighted average basic and diluted loss per share of $2.03. Cash and cash equivalents were $9.5 million at June 30, 2025, and the company had an accumulated deficit of $2.2 billion and total assets of $185.2 million. The balance sheet shows a large recorded liability related to sale of future royalties and milestones, net of $312.2 million, current liabilities of $234.6 million and stockholders’ deficit attributable to Agenus of $354.6 million.
The company received $75.0 million gross proceeds from the Ligand Purchase Agreement (allocated partly to a royalty liability) and recognized $48.4 million of non-cash royalty revenue in the six months. Subsequent to quarter end it sold ~787,000 shares for net proceeds of ~$5.2 million and expects to receive $75.0 million upfront plus a $16.0 million equity investment from the Zydus transaction upon closing in Q3 2025. Management discloses substantial doubt about going concern for one year after filing and notes ongoing litigation and an SEC subpoena.
Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc. (AGEN), received 3,407 shares of common stock in lieu of cash salary for the pay period ending August 8, 2025. The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and the company reports a closing price of $4.80 on August 8, 2025.
After the issuance, Dr. Armen directly beneficially owns 267,311 shares. He also reports 31,298 shares held in his IRA accounts and 28,950 shares held indirectly through a GRAT and a partnership where he has a partial pecuniary interest. The filing states the issued shares are fully vested on the date of issuance.
Agenus Inc. announced its financial results for the quarter ended June 30, 2025 and furnished a related press release as Exhibit 99.1 to this current report. The 8-K notes the press release is being furnished with the report rather than being filed.
The filing explicitly states the information furnished is not intended to be "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings except by specific reference. The 8-K itself does not include financial tables or detailed results within the filing text.
Investors should consult the furnished press release (Exhibit 99.1) for the company’s reported metrics; the 8-K serves to disclose the existence of that press release and the company’s disclosure status.